SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-287345
Filing Date
2020-11-06
Accepted
2020-11-06 06:47:32
Documents
14
Period of Report
2020-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d102044d8k.htm   iXBRL 8-K 25220
2 EX-99.1 d102044dex991.htm EX-99.1 117152
6 GRAPHIC g102044g1104223710520.jpg GRAPHIC 2825
  Complete submission text file 0001193125-20-287345.txt   280132

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epzm-20201106.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epzm-20201106_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epzm-20201106_pre.xml EX-101.PRE 10950
7 EXTRACTED XBRL INSTANCE DOCUMENT d102044d8k_htm.xml XML 3218
Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Filer) CIK: 0001571498 (see all company filings)

IRS No.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35945 | Film No.: 201292346
SIC: 2834 Pharmaceutical Preparations